Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

The Food and Drug Administration (FDA) has approved Datroway ® (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human ...

DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...

AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...

A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone ...